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ABSTRACT 
Interactions   between secreted immune proteins 
called chemokines and their cognate G protein–
coupled receptors regulate the trafficking of 
leukocytes in inflammatory responses. The two-
site, two-step model describes these interactions. 
It involves initial binding of the chemokine N-
loop/3 region to the receptor’s N-terminal 
region and subsequent insertion of the chemokine 
N-terminal region into the transmembrane helical 
bundle of the receptor concurrent with receptor 
activation. Here we test aspects of this model with 
CC motif chemokine receptor 1 (CCR1) and 
several chemokine ligands. First, we compared 
the chemokine-binding affinities of CCR1 with 
those of peptides corresponding to the CCR1 N-
terminal region. Relatively low affinities of the 
peptides and poor correlations between CCR1 
and peptide affinities indicated that other regions 
of the receptor may contribute to binding affinity. 
Second, we evaluated the contributions of the two 
CCR1-interacting regions of the cognate 
chemokine ligand CCL7 (formerly monocyte 
chemoattractant protein-3, MCP-3) using 
chimeras between CCL7 and the non-cognate 
ligand CCL2 (formerly MCP-1). The results 
revealed that the chemokine N-terminal region 
contributes significantly to binding affinity but 
that differences in binding affinity do not 
completely account for differences in receptor 
activation. On the basis of these observations, we 
propose an elaboration of the two-site, two-step 
model— the “three-step” model—in which initial 
interactions of the first site result in low-affinity, 
non-specific binding; rate-limiting engagement 
of the second site enables high-affinity, specific 
binding; and subsequent conformational 
rearrangement gives rise to receptor activation. 
 
The interactions between chemokines and 
chemokine receptors regulate the trafficking of 
leukocytes, a key feature of inflammatory 
responses (1,2). Chemokines are small proteins 
secreted by various tissues as part of normal 
immune surveillance or in response to tissue 
injury or infection. Chemokines bind to and 
activate chemokine receptors, which are G 
protein-coupled receptors (GPCRs) expressed in 
leukocyte cell membranes. This initiates 
intracellular signal transduction leading to 
changes in leukocyte morphology and adhesion 
and ultimately giving rise to accumulation of 
leukocytes in the affected tissues. Due to the 
importance of this process in numerous 
inflammatory diseases, there is substantial 
interest in understanding the detailed molecular 
mechanisms of chemokine-receptor interactions 
and signaling. 
CCR1, a member of the CC chemokine 
receptor subfamily, is expressed on the surfaces 
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of monocytes, natural killer cells and immature 
myeloid cells (3,4). At least nine CC chemokines 
are reported to be cognate agonists of CCR1 (5). 
Activation of CCR1 has been implicated in the 
pathology of rheumatoid arthritis (6), multiple 
sclerosis (7),	multiple myeloma (8,9), transplant 
rejection (10), diabetes (11), osteopenia (12) and 
progressive kidney disease (13). As with other 
chemokine receptors, clinical trials targeting 
CCR1 with anti-inflammatory drug candidates 
have not been successful to date but CCR1 is still 
considered a valid therapeutic target (14). 
Numerous studies have investigated the 
molecular determinants of chemokine receptor 
binding and activation. Early studies identified 
two distinct regions of chemokines that interact 
with distinct regions of their receptors (15). The 
chemokine “N-loop” and nearby 3 region, 
together defined as chemokine site 1 (CS1), were 
found to bind to peptides corresponding to the 
flexible N-terminal regions of chemokine 
receptors, defined as chemokine receptor site 1 
(CRS1). In addition, the N-terminal region of the 
chemokine (CS2) was found to be critical for 
receptor activation, so it was proposed that this 
region interacts with a second site on the receptor 
(CRS2), later found to be predominantly located 
within the transmembrane (TM) bundle of the 
receptor, with some contributions from 
extracellular loops (16,17). 
Based on these early observations, Crump 
et al. proposed the two-site, two-step model as a 
general paradigm for chemokine-receptor 
interactions (15). According to this model, CS1-
CRS1 form first and contribute to binding without 
receptor activation. Subsequently, engagement of 
CS2 with CRS2 induces a conformational change 
and receptor activation. This model remains 
consistent with much of the available functional 
and structural data, including a study of chimeric 
receptors formed by exchanging regions of CCR1 
and the related receptor CCR3 (18). However, a 
number of observations point to possible 
deficiencies in this simple model. In particular, 
mutations in CS2 can influence receptor binding 
affinity, suggesting that binding and activation 
are not simply partitioned between the two 
structural sites (19,20). Similarly, different 
chemokine agonists of the same receptor can 
selectively interact with different regions of a 
receptor (21) or can “bias” a shared receptor 
towards activation of different signaling 
pathways (22,23), suggesting distinct activated 
conformations of the receptor. Moreover, recent 
structural data and models indicate that residues 
outside of the two primary sites may also make 
important contributions to binding and receptor 
activation (16,24). As discussed in a detailed 
review by Volkman and colleagues (25), there is 
a need to consider possible elaborations of the 
two-site, two-step model.  
In the study described herein, we have 
taken two approaches to evaluate specific aspects 
of the two-site, two-step model for CCR1 and 
several of its chemokine ligands. First, we have 
compared the chemokine binding affinities of 
CCR1 to those of peptides corresponding to the 
N-terminus (CRS1) of CCR1, allowing us to 
evaluate the contributions of CRS1 to both 
affinity and selectivity of chemokine binding. 
Second, we have compared CCR1 binding and 
activation by chimeric chemokines derived from 
a high affinity cognate chemokine and a low 
affinity chemokine, enabling the contributions of 
CS1 and CS2 to be evaluated. The data indicated 
that CS2-CRS2 interactions contribute 
significantly to binding affinity but that 
differences in binding affinity do not completely 
account for differences in receptor activation. 
These results prompted us to propose an 
extension of the two-site, two-step model (the 
“three-step” model) in which: initial CS1-CRS1 
interactions result in low affinity, non-specific 
binding; rate-limiting engagement of CS2 with 
CRS2 enables high affinity, specific binding; and 
subsequent conformational rearrangement gives 
rise to receptor activation. 
 
RESULTS 
Chemokine Binding to N-terminal CCR1 
Peptides – The N-terminal regions of chemokine 
receptors are thought to be flexible and 
essentially unstructured. Therefore, peptides 
corresponding to this region are often used as 
simplified models of CRS1 (26-38).  If the site 1 
interactions make a major contribution to the 
binding interactions, one would anticipate that the 
binding free energy of such N-terminal peptides 
for chemokines would be a substantial proportion 
of the binding free energy of intact receptors for 
the same chemokines. Moreover, it would be 
expected that the binding free energies (or 
affinities) of several chemokines would correlate 
for the N-terminal peptides and the intact 
receptors. To test these hypotheses, we measured 
the binding affinities of peptides with the N-
terminal sequence of CCR1 and of intact CCR1 
expressed on mammalian cells to each of four 
cognate chemokine ligands (CCL15/HCC-2, 
CCL5/RANTES, CCL7/MCP-3 and 
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CCL8/MCP-2) as well as two chemokines that 
are not usually considered cognate ligands of 
CCR1 (CCL2/MCP-1 and CCL26/eotaxin-3). 
The N-terminus of CCR1 contains two 
predicted sites of tyrosine sulfation (Tyr-10 and 
Tyr-18) (39), although it has not been determined 
whether these sites are actually sulfated in CCR1; 
sulfation could also be incomplete or vary for 
different cell types. Considering that sulfation in 
the N-terminal regions of chemokine receptors 
can alter both the affinity and selectivity of 
chemokine binding (40), we prepared a set of 
peptides with all four possible combinations of 
sulfation at these two sites (Fig 1A) and used an 
established competitive fluorescence anisotropy 
binding assay (41) to measure their binding 
affinities for the six chemokines (Fig 1B-G, Table 
1; Fig S1, Table S1). Affinities ranged from ~40 
nM to ~24 M and were well correlated between 
different peptides (r2 = 0.70 to 0.98; Fig S2), 
indicating that sulfation has only a small 
influence on the selectivity of the CCR1 N-
terminal peptide for chemokine ligands. 
Contribution of Site 1 Interactions to 
CCR1 Binding Affinity and Selectivity – We 
assessed the affinities of chemokines for CCR1 
expressed in Flp-In T-REx human embryonic 
kidney (HEK) 293 cells using a radioligand 
displacement assay (Fig 2A,B and Table 2). The 
results are consistent with previous reports of 
chemokine-CCR1 binding affinities (42-44). 
Although the sulfation status of CCR1 is 
unknown, we also determined the affinities of the 
same chemokines for CCR1 derived from cells 
treated with 30 mM chlorate, which blocks 
tyrosine sulfation. Effective prevention of 
sulfation by 30 mM chlorate was verified using 
ELISA for two chemokine receptors N-terminally 
tagged with both FLAG, for which antibody 
detection is blocked by sulfation (45), and cMyc, 
which cannot be sulfated (Fig S3). We found that 
the chemokine affinities were not significantly 
different for CCR1 derived from untreated cells 
and cells treated with 30 mM chlorate (Fig 2A,B 
and Table 2). This indicates that either CCR1 is 
not sulfated in these cells or sulfation has no 
effect on chemokine affinity.  
As expected, the affinities of chemokines 
were higher for CCR1 than for the N-terminal 
peptides. For most chemokines, the intact 
receptor bound with affinities in the range 0.07-
60 nM, whereas the peptides bound about 1000-
fold less tightly. These data indicate that, in 
general, approximately two-thirds of the receptor 
binding free energy can be attributed to the 
interactions at site 1. The only exception was 
CCL26, which bound to the peptides (Kd ~0.1-4 
M) but for which CCR1 binding could not be 
detected at concentrations up to 0.1 M. CCL26 
is not a cognate ligand for CCR1. It is possible 
that this chemokine binds to CRS1 of CCR1 with 
an affinity comparable to its affinity for the non-
sulfated N-terminal peptide but without any 
additional interactions with CRS2. 
To assess the contribution of the receptor 
N-terminus to the selectivity of receptor binding, 
sulfopeptide binding affinities (pKd) were 
correlated with intact receptor binding affinities 
(pIC50). In all cases, the correlations were very 
poor (r2 = 0.02 to 0.16; Fig 3). One possible 
explanation for such poor correlations is that the 
interactions of the chemokines at CRS1 may 
differ substantially for the intact receptor and the 
receptor derived peptides, or be substantially 
influenced by local structural constraints in the 
intact receptor. An alternative explanation is that 
CRS1 interactions alone do not play a dominant 
role in defining the chemokine binding selectivity 
and additional interactions of CRS2 also 
contribute. 
Evaluation of Site 1 and Site 2 interactions 
using Chemokine Chimeras – The chemokine 
CCL7 is a potent cognate ligand for CCR1 (42), 
whereas the closely related chemokine CCL2 has 
much lower potency and affinity for CCR1 and is 
not generally considered a cognate ligand for this 
receptor. Therefore, these two chemokines 
present an opportunity to dissect the contributions 
of different structural elements of chemokines to 
CCR1 binding and activation.  For this purpose 
we used two sets of chimeric chemokines based 
on CCL2 and CCL7 (Fig 4; includes 
nomenclature); we used the obligate monomeric 
mutant CCL2(P8A) to ensure consistency with 
the naturally monomeric CCL7 (46,47). In each 
chimera, one of three key regions for receptor 
recognition (N-terminus, N-loop and 3 region) 
was substituted for the corresponding region from 
the other chemokine or all three regions were 
substituted together. To avoid disrupting the 
folded structures of the chemokines, hydrophobic 
core residues were excluded from being replaced. 
As described in a previous study of their 
interactions with CCR2, all of the chimeras are 
well folded (20). 
For the parental chemokines and each 
chimera, we evaluated binding to CCR1 using the 
radioligand displacement assay. In addition, we 
measured signaling via CCR1 expressed on Flp-
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In T-REx 293 cells using  proximal 
measurements of receptor activation (recruitment 
of -Arrestin 2; Arr and G protein activation) 
and two downstream, amplified signals: 
inhibition of cAMP production; and 
phosphorylation of extracellular signal-regulated 
kinases 1 and 2 (ERK1/2). 
As expected, CCL7 bound with 
significantly higher affinity than CCL2 to CCR1 
(pIC50 values of 9.0 ± 0.1 and 7.2 ± 0.2, 
respectively, p < 0.0001; Fig 5A, Table 3), 
exhibited a higher maximal effect (Emax) in the 
proximal Arr assay (p = 0.0046; Fig 5B, Table 
3) and displayed higher potency (pEC50) in the 
three amplified signaling assays (p ≤ 0.0001, Fig 
5C-E, Table 3). These data indicate that, relative 
to CCL7, CCL2 is a partial agonist of CCR1. 
The chimera in which all three regions of 
CCL7 were replaced by those of CCL2 (CCL7-
222) had CCR1 binding affinity very similar to 
that of CCL2, whereas the inverse chimera 
(CCL2-777) had CCR1 binding affinity very 
similar to that of CCL7 (Fig 5A-E, Table 3). In 
addition, the chimera CCL7-222 displayed the 
partial agonist activity of CCL2 whereas CCL2-
777 displays the full agonism of CCL7. This trend 
was observed in all four measurements of 
receptor activation. These results verify that the 
three swapped regions are the primary regions of 
these two chemokines responsible for their 
differences in CCR1 binding and activation. 
Contributions of Chemokine N-loop and 3 
Regions to CCR1 Binding and Activation – 
According to the two-site model the N-loop and 
3 regions of chemokines, which together 
constitute CS1, are expected to contribute to 
receptor binding affinity. We found that 
replacement of the 3 region of CCL2 with that 
of CCL7 (chimera CCL2-227) or the inverse 
replacement (chimera CCL7-772) had little 
influence on CCR1 binding affinity or on the 
signaling profiles of these chemokines (Fig 6A-E, 
Table 3). On the other hand, replacement of the 
N-loop of CCL2 with that of CCL7 (chimera 
CCL2-272) increased the CCR1 binding affinity 
to be the same as that of wild type CCL7, whereas 
replacement of the N-loop of CCL7 with that of 
CCL2 (chimera CCL7-727) decreased the 
binding affinity to be similar to that of CCL2 (Fig 
7A, Table 3). Interestingly, these two chimeras 
displayed signaling profiles in all four assays that 
were intermediate between the full agonism of 
CCL7 and the partial agonism of CCL2 (Fig 7B-
E, Table 3). This indicates that the replacement of 
the N-loop alone is not sufficient to completely 
overcome the differences in receptor activation 
despite conferring the affinity of the donor 
chemokine. 
Contribution of Chemokine N-terminus to 
CCR1 Binding and Activation – In the two-site 
two-step model, the chemokine N-terminus (CS2) 
is not involved in initial binding interactions but 
engages with the receptor TM region (CRS2) in 
the second step to activate the receptor. However, 
we observed that swapping the N-terminus gives 
chimeras (CCL2-722 and CCL7-277) that display 
an intermediate CCR1 affinity between those of 
the parental chemokines (Fig 8A, Table 3). This 
indicates that the N-terminus does contribute to 
binding affinity. The activation profiles of these 
chimeras were also intermediate between those of 
the full and partial agonist activities of the 
parental chemokines (Fig 8B-D, Table 3). This 
suggests that the N-terminal region of the 
chemokines contributes not only to activation of 
the receptor but is also a determinant of high 
affinity binding. 
 
DISCUSSION 
The two-site, two-step model suggests that 
most of the binding energy is provided by site 1 
interactions. In this study, we observed that 
peptides derived from the N-terminal region 
(CRS1) of CCR1 bind to cognate chemokines 
with affinities ranging from ~40 nM to ~24 M. 
In comparison, CCR1 on cell membranes bound 
to the same chemokines with affinities of ~70 pM 
to ~2 nM. It is not straightforward to deduce the 
relative free energies of binding interactions at 
each site because both receptor binding and 
peptide binding is expected to be accompanied by 
loss of overall rotational and translational entropy. 
Moreover, the peptides used here (and those used 
in other studies) may differ substantially in their 
structural ensembles and constraints from the N-
terminal region of the intact receptor. 
Nevertheless, under the assumption that the 
affinities of the peptides are a reasonable 
approximation of the contributions of site 1 to 
binding affinity, our data indicate that the site 1 
interactions contribute at least ~50% of the total 
free energy for chemokine-receptor binding if the 
receptor is not sulfated and ~60-90% (depending 
on the chemokine) of the total binding free energy 
if the receptor is sulfated at both possible sites. 
This conclusion can be taken as supporting the 
importance of site 1 for binding. However, it also 
highlights that subsequent interactions may also 
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contribute a substantial proportion of binding free 
energy. 
Two aspects of the peptide binding data 
point to possible deficiencies in the two-site, two-
step model. First, we found that the N-terminal 
peptides bound to two non-cognate chemokines 
of CCR1 (CCL2 and CCL26) with affinities 
comparable to those of cognate ligands; as 
expected, these chemokines bound more weakly 
than the cognate ligands to CCR1 on cell 
membranes. Second, there was no correlation 
between peptide affinities and receptor affinities 
(Fig 3), indicating that site 1 interactions may not 
play a dominant role in controlling the chemokine 
selectivity of the receptor. These observations 
suggest that site 1 may be the initial site of 
chemokine binding for both cognate and non-
cognate ligands, but that additional interactions 
are required for selective recognition of cognate 
ligands. 
The CCR1 binding affinities of the 
CCL7/CCL2 chimeras support the contention that 
both sites 1 and 2 contribute to binding affinity. 
Whereas substitution of the N-loop (CS1) was 
sufficient to almost completely swap the affinity 
of one chemokine to that of the other, substitution 
of the N-terminus (CS2) also changed the affinity 
of each chemokine to be closer to that of the other. 
Importantly, the affinity contributions of these 
two regions were not simply additive, indicating 
that the interactions of one region influence those 
of the other. Our conclusion that site 2 contributes 
to chemokine-receptor binding is consistent with 
a study of CCR1-CCR2 chimeric receptors in 
which regions other than the receptor N-terminus 
were found to be required for high affinity 
binding of the CCR1 ligand CCL3/MIP-1 (48). 
The CCL7/CCL2 chimeras also provided 
insights into the roles of chemokine structural 
regions in receptor activation. Our data indicate 
that both the N-terminal region and the N-loop 
contribute to the higher efficacy of CCR1 
activation (e.g. Emax in the proximal Arr assay) 
by the full agonist CCL7 compared to the partial 
agonist CCL2. The contribution of the N-terminal 
region (CS2) is expected for the two-site, two-
step model. However, the contribution of the N-
loop (CS1) again suggests interdependence of the 
site 1 and site 2 interactions, possibly mediated by 
some of the additional interactions identified by 
structural modeling (24). These results are 
consistent with the observation of Pease et al. that 
both the N-terminal region and elements outside 
of the N-terminal region are required to support 
CCR1 activation by CCL3 (18). 
In summary, the results described here 
indicate that both sites 1 and 2 contribute to 
binding interactions but that high affinity receptor 
binding is not sufficient to give rise to full 
receptor activation. These results can be 
rationalized by a fairly simple elaboration of the 
two-site, two-step model to a “three-step” model 
(Fig 9), in which: step 1 involves non-specific, 
low-affinity binding between CS1 and CRS1; 
step 2 represents specific binding and involves 
engagement of CS2 with CRS2, possibly 
accompanied by formation of additional 
interactions outside the two principal sites; and 
step 3 involves a conformational change of the 
chemokine-receptor complex resulting in 
receptor activation and transmembrane signaling. 
The proposed three-step model can be used 
to understand the interactions of a chemokine 
receptor with a variety of different types of 
chemokine ligands (Fig 9). Non-cognate 
chemokines would participate in step 1 but not in 
subsequent steps. Cognate chemokine antagonists 
(or inverse agonists) would participate in steps 1 
and 2 but not enable receptor activation. 
Chemokine agonists would participate in all 3 
steps and would shift the equilibrium between the 
inactive state and the activated state; full agonists 
would shift this equilibrium strongly towards the 
activated state, whereas partial agonists would 
shift it less strongly.   
The proposal that site 1 is involved in non-
specific binding but that additional interactions 
are required for specific binding is supported by 
considerations of binding thermodynamics. 
Physiological concentrations of chemokines are 
typically thought to be in the low nanomolar 
range, although there remains some uncertainty 
about effective local concentrations, which are 
expected to be influenced by factors such as 
oligomerization and glycosaminoglycan binding. 
Thus, the relatively low affinities of chemokines 
for the N-terminal regions of their receptors (Kd 
values in the high nanomolar to low micromolar 
range) indicates that there will be a relatively low 
(probably <10%) occupancy of receptor site 1 in 
the absence of additional interactions. On the 
other hand, the high affinities of intact receptors 
for cognate chemokines (Kd values ≤ ~1 nM) will 
result in high (perhaps >90%) receptor occupancy. 
It is also important to consider the kinetics 
of binding interactions. Previous NMR studies 
from our lab and others (26-38) have shown that 
binding of both cognate and non-cognate 
chemokines to receptor N-terminal peptides is 
typically fast (dissociation rate constants koff >> 1 
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s-1), whereas dissociation of cognate chemokines 
from their receptors is much slower (koff << 0.1 s-
1), as required for radioligand binding assays. 
Moreover, conformational transitions from 
inactive to active states of GPCRs occur with rate 
constants on the order of ~1 s-1 (49). These kinetic 
considerations suggest that cognate and non-
cognate chemokines may bind to and dissociate 
from site 1 of a receptor many times before a 
cognate chemokine engages receptor site 2, 
giving rise to a conformational change and 
receptor activation. Thus, within the proposed 
three-step model, step 1 is likely to represent a 
rapid pre-equilibrium process, whereas step 2 is 
likely to be the rate-determining step, as indicated 
by the free energy profiles in Fig 9. 
Conclusion – We have proposed a simple 
three-step model to account for the contributions 
of site 2 interactions to chemokine-receptor 
binding affinity and to separate high affinity 
binding from receptor activation. This model 
extends the popular two-site, two-step model and 
may serve as an improved paradigm for 
interpretation of structure-function and 
mechanistic experiments. Further elaboration of 
this model would be possible to incorporate such 
phenomena as allosteric receptor interactions and 
ligand-biased receptor activation. 
 
EXPERIMENTAL PROCEDURES 
Materials – Dulbecco’s Modified Eagle 
Medium (DMEM) and Hanks’s balanced salt 
solution (HBSS) were purchased from Invitrogen. 
Blasticidin and Hygromycin B were purchased 
from InvivoGen (San Diego, CA). Fetal bovine 
serum was purchased from In Vitro Technologies 
(Noble Park, VIC, Australia). Polyethyleneimine 
(PEI) was purchased from Polysciences, Inc. 
(Warrington, PA). Coelenterazine h was 
purchased from NanoLight (Pinetop, AZ). 
Sulfopeptides were synthesised and their 
concentrations determined as described (50,51). 
Unless otherwise noted, all the other reagents 
were purchased from Sigma-Aldrich.  
Chemokine Expression and Purification – 
CCL2 and all chimeras containing the N-terminal 
region of CCL2 contain the P8A mutation to 
ensure these proteins are monomeric. The form of 
CCL15 used in this study is the active, high 
affinity form CCL15(26), which has the N-
terminal sequence HFAAD (52). All chemokines 
and chimeras were expressed and purified as 
described (20,46). Briefly, the N-terminal His6-
tagged protein was expressed from BL21 (DE3) 
E.coli in LB media by induction with IPTG. 
Inclusion bodies containing the fusion (i.e. His6-
tagged) proteins were isolated and dissolved in 
denaturing buffer and then purified by Ni2+-
affinity chromatography. The fusion protein was 
refolded by rapid dilution, the His6-tag was 
removed using human thrombin or TEV protease 
and the untagged protein (containing the native 
N-terminus) was further purified by size 
exclusion chromatography. Purity was evaluated 
by SDS-PAGE and protein identity was 
confirmed by MALDI-TOF mass spectrometry. 
Fluorescence Anisotropy Assay – Peptides 
R1A-R1D (Fig 1A) and Fl-R2D (Fig 1A) were 
prepared by solid phase peptide synthesis and 
purified by HPLC, as described (41). Samples for 
fluorescence anisotropy binding assays were 
prepared in 50 mM MOPS buffer (pH 7.4) using 
Greiner non-binding, black, flat-bottomed, 96-
well microplates and a final volume of 200 L per 
well. Direct binding assays were performed using 
final chemokine concentrations of 31-2000 nM 
(2-fold increments) and a final concentration of 
fluorescent sulfopeptide Fl-R2D of 10 nM. 
Competitive binding assays were performed 
using invariable final concentrations of the 
chemokine (100-500 nM; chosen to have ~80 % 
of the chemokine bound to the probe) and Fl-R2D 
(10 nM) and with a range of concentrations for 
the competitor (non-fluorescent sulfopeptides 
R1A-R1D), serially 2-fold diluted from the 
highest final concentrations of 100 µM (for R1A), 
50 µM (for R1B, R1C) and 10 µM (for R1D). 
After 5 min, fluorescence anisotropy was 
measured at 25 °C using a PHERAstar plate 
reader (BMG Labtech, Ortenberg, Germany) 
equipped with a fluorescence polarisation module 
with dedicated excitation and emission 
wavelengths of 485 and 520 nm respectively. 
Assays were performed in duplicate, three times 
independently. 
Mammalian Cell Culture – Assays (except 
the β-arrestin recruitment assay) were performed 
using Flp-In™ T-REx™ 293 cells (Invitrogen) 
stably transfected with the plasmid 
pcDNA5/FRT/TO-His6-cMyc-CCR1 to express 
human CCR1 with N-terminal His6 and cMyc 
tags. Cells were grown and maintained in full 
media comprised of Dulbecco’s modified eagle 
medium (DMEM, Gibco) supplemented with 5% 
(v/v) tetracyclin-free fetal bovine serum (FBS, 
Gibco), 5 μg/mL blasticidin to maintain selection 
of cells stably transfected with the tetracyclin 
repressor gene (tetR) and 200 μg/mL hygromycin 
B to maintain selection of cells stably transfected 
with the CCR1 gene. Cells were grown and 
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maintained at 37 °C in 5% CO2 in 175 cm2 flasks 
and were detached from the flask by washing with 
versene (PBS/EDTA), followed by incubation in 
1% (w/v) trypsin in versene for 5 minutes. 
Tyrosine sulfation was inhibited 48 hours prior to 
each experiment by addition of 30 mM sodium 
chlorate to cell media. Receptor expression was 
induced 24 hours prior to each experiment by 
addition of 10 μg/mL tetracycline to cell media. 
Membrane Preparation – Cell membranes 
were prepared by detaching the cells from the 
flasks, centrifugation at 1500 g for 3 min and 
resuspension in ice-cold 50 mM MOPS buffer 
containing 5 mM MgCl2 and 0.1% 3-[(3-
cholamidopropyl)-dimethylammonio]-1-
propanesulfonic acid (CHAPS), pH 7.4. The 
lysates were homogenized by sonication and 
centrifuged at low speed for 5 min. Membrane 
and cytosolic fractions were separated by 
centrifugation at 40,000 rcf for 30 min at 4 °C. 
The pellet containing membranes was 
resuspended in MOPS buffer containing 5 mM 
MgCl2 and 0.1% CHAPS, pH 7.4 and stored 
at -20 °C. Protein concentrations were measured 
using a BCA protein determination assay (53). 
Radioligand binding assays – Competitive 
binding assays were performed as described by 
Zweemer et al. (54). Briefly, binding assays were 
performed in a 100-µL reaction volume 
containing 50 mM MOPS buffer (pH 7.4), 5 mM 
MgCl2, 0.1% CHAPS, 10 μg of membranes, 
variable concentrations of chemokines and 50 pM 
125I- CCL3 (PerkinElmer). Nonspecific binding 
was determined in the presence of 10 μM BX471, 
a CCR1 antagonist. Samples were incubated for 2 
h at 37 °C. Binding was terminated by dilution 
with ice-cold 50 mM MOPS buffer (pH 7.4) 
supplemented with 0.05% CHAPS and 0.5 M 
NaCl, followed by rapid filtration through a 96-
well GF/C filter plate precoated with 0.5% PEI 
using a Filtermate-harvester (Perkin Elmer). 
Filters were washed 3 times with the same ice-
cold wash buffer, dried at 50 °C, and 25 μL of 
MicroScint-O scintillation cocktail 
(PerkinElmer) was added to each well. 
Radioactivity was determined using a MicroBeta2 
LumiJET 2460 Microplate Counter 
(PerkinElmer). 
-Arrestin Recruitment Assay – 
Recruitment of β-arrestin-2 to CCR1 was 
assessed in Flp-In™ T-REx™ 293 cells 
transiently transfected with CCR1-RLuc8 and β-
arrestin-2-YFP as described previously (55). 
Briefly, CCR1-RLuc8 and β-arrestin-2-YFP were 
transfected at a receptor:arrestin ratio of 1:4 using 
PEI at a DNA:PEI ratio of 1:6 (56). After 24 h, 
cells were re-plated in poly-D-Lysine-coated 96-
well white opaque CulturPlates (PerkinElmer) 
then, 48 h after transfection, cells were rinsed and 
pre-incubated in Hank’s Balanced Saline 
Solution (HBSS) for 30 min at 37 °C. 
Coelenterazine h was added to each well (final 
concentration 5 μM) followed by the addition of 
receptor ligands 5 min later. Cells were incubated 
for a further 10 min in the dark at 37 °C. BRET 
measurements were obtained using a PHERAstar 
plate reader (BMG Labtech, Ortenberg, 
Germany) that allows for sequential integration of 
the signals detected at 475 ± 30 and 535 ± 30 nm, 
using filters with the appropriate band pass. Data 
are presented as a ligand-induced BRET ratio 
(baseline-corrected by subtracting the BRET ratio 
of vehicle treated cells). All experiments were 
performed in duplicate and repeated 
independently at least 3 times. 
ERK1/2 phosphorylation – 
Phosphorylation of ERK1/2 was measured using 
the AlphaScreen® SureFire® p-ERK 1/2 
(Thr202/Tyr204) Assay Kit (PerkinElmer, TGR 
biosciences) following the manufacturer’s 
instructions. Briefly, 4 x105 cells/well were 
seeded in a poly-D-Lysine-coated plate in full 
media containing 10 μg/mL tetracycline and 
serum-starved overnight. Initial time-course 
experiments determined that peak levels of ERK 
1/2 phosphorylation were achieved 5 minutes 
after the addition of chemokines. Therefore, for 
all concentration-response experiments, cells 
were stimulated with chemokine for 5 minutes at 
37 °C. 10 % v/v FBS was used as a positive 
control. The reaction was terminated by removal 
of the media and addition of SureFire lysis buffer 
(100 µL). Cell lysis was assisted by shaking the 
plates at 600 rpm for 5 minutes. 5 µL of lysate 
was transferred to a white 384-well Proxiplate™ 
followed by the addition of 8 µL of SureFire 
AlphaScreen Detection Mix (240:1440:7:7 v/v 
dilution of SureFire Activation Buffer: SureFire 
Reaction Buffer: AlphaScreen Acceptor Beads: 
AlphaScreen Donor Beads). The plate was 
incubated in the dark for 1.5 h at 37 °C and the 
AlphaScreen signal was read on an Envision® 
plate reader (PerkinElmer). Data were normalized 
to the signal in the absence of chemokine (0 % 
response) and in the presence of 10 % v/v FBS 
(100 % response). All experiments were 
performed in duplicate and repeated 
independently at least 3 times. 
Inhibition of forskolin-induced cAMP 
production – Cells were plated in a Petri dish 
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(about 2.5 x 106 cells per dish) and allowed to 
grow overnight in full media at 37 °C, 5 % CO2. 
The following day, cells were transfected with a 
CAMYEL cAMP BRET biosensor (56). 
Transient transfection was performed using PEI 
at a DNA:PEI ratio of 1:6. After 24 h, cells were 
re-plated in poly-D-Lysine-coated 96-well white 
opaque CulturPlates (PerkinElmer). 48h after 
transfection cells were rinsed and pre-incubated 
in Hank’s Balanced Saline Solution (HBSS) for 
30 min at 37 °C. Cells were then incubated with 
the RLuc substrate coelenterazine h (final 
concentration 5 µM) for 5 min, followed by a 
further 5 min incubation with various 
concentrations of chemokine. Forskolin was then 
added for an additional 5 min to a final 
concentration of 10 µM. BRET measurements 
were obtained using a PHERAstar plate reader 
(BMG Labtech, Ortenberg, Germany) that allows 
for sequential integration of the signals detected 
at 475 ± 30 and 535 ± 30 nm, using filters with 
the appropriate band pass. BRET ratio was 
calculated as the ratio of YFP to RLuc signals, 
and data are expressed as the percentage of the 
forskolin-induced signal. 
G protein activation assay – Cells were 
plated in a Petri dish (~2.5 x 106 cells per dish) 
and allowed to grow in full media at 37 °C in 5 % 
CO2 overnight. The following day, cells were 
transfected in full media using DNA ratios of 
2:1:1:1 for Gαi: Gβ-Venus(C-terminus):Gγ-
Venus(N-terminus): masGRK3-ct-Rluc (57) and 
a 1:6 total DNA to PEI ratio. Cells were allowed 
to grow in transfection media mix for 24 hours at 
37 °C, 5 % CO2. Cells were then replated in a 
poly-D-lysine-coated 96-well white-bottom 
Culturplate in full media containing 10 µg/mL 
tetracycline and allowed to grow for another 24 
hours. Cells were then washed once with 100 μL 
of HBSS and incubated in fresh HBSS for ~30 
min at 37 °C. Cells were stimulated in HBSS to a 
total volume of 100 µL per well. The Rluc 
substrate coelenterazine h was added to each well 
(final concentration of 5 µM) and cells were 
incubated for 5 minutes at 37 °C. After 5 minutes, 
cells were stimulated with chemokines and 
incubated for a further 10 minutes at 37 °C. Venus 
and Rluc emission signals (535 and 475 nm 
respectively) were measured using a PHERAstar 
plate reader and the ratio of Venus:Rluc was used 
to quantify relative levels of trimeric G protein 
dissociation in each well. Data are presented as a 
ligand-induced BRET ratio (baseline-corrected 
by subtracting the BRET ratio of vehicle treated 
cells). All experiments were performed in 
duplicate and at least three times independently. 
Data analysis and Statistics – All data 
points represent the mean and error bars represent 
the standard error of the mean (SEM) of at least 
three independent experiments. Data were 
analyzed using Prism 6.0 (GraphPad Software 
Inc., San Diego, CA). 
Direct fluorescence anisotropy binding 
data were fitted with a non-linear 1:1 binding 
equilibrium model described by the equation:  
ܻ ൌ Y௜ ൅ ൫Y௙ െ Y௜൯ ൈ ቀ ଵଶ୔೟ቁ ൣሺP௧ ൅ L௧ ൅ Kௗሻ െ
ඥሺሺ ௧ܲ ൅ ܮ௧ ൅ ܭௗሻଶ െ 4P௧L௧ሻ൧ (Equation 1)  
in which: Y is the observed anisotropy; Yi and Yf 
are the initial and final anisotropy, respectively; 
Pt is the total concentration of Fl-R2D; Lt is the 
total concentration of the chemokine; and Kd is 
the fitted equilibrium dissociation constant. 
Competitive fluorescence anisotropy 
binding data were fitted with the non-linear 1:1 
competitive displacement equation derived by 
Huff et al. (58), in which the concentration of the 
non-fluorescent peptide was the independent 
variable while the dependent variable was the 
observed anisotropy. Fixed input parameters 
were: the total concentrations of Fl-R2D and 
chemokine; the final anisotropy value which 
corresponds to the anisotropy of free Fl-R2D; and 
the affinity between Fl-R2D and chemokine (Kd 
value obtained from the direct binding assay). 
The fitted parameters were the initial anisotropy 
and the log(Kd) between the competitor and the 
chemokine. 
For radioligand binding, the concentration 
of agonist that inhibited half of the 125I-CCL3 
binding (IC50) was determined using the equation:  
ܻ ൌ 	஻௢௧௧௢௠ାሺ௧௢௣ି௕௢௧௧௢௠ሻଵା	ଵ଴ሺ೉ష೗೚೒಺಴ఱబሻ೙ಹ   (Equation 2) 
in which: Y denotes the percentage specific 
binding; top and bottom denote the maximal and 
minimal asymptotes, respectively, of the 
concentration–response curve; IC50 denotes the 
X-value when the response is midway between 
Bottom and Top; and nH denotes the Hill slope 
factor.  
All data from concentration-response 
signaling assays were normalized as outlined 
above and fitted to the equation: 
 (Equation 3) 
in which: top and bottom represent the maximal 
and minimal asymptotes of the concentration–
response curve; [A] is the molar concentration of 
agonist; and EC50 is the molar concentration of 
Y  bottom  top  bottom
110(log EC50  log[A ])
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agonist required to give a response half way 
between bottom and top. 
All statistical comparisons were performed 
using (negative) logarithmic parameters (pKd, 
pIC50 or pEC50) as distributions of these 
parameters are approximately Gaussian (59). 
Multiple T test comparison with Holm-Sidak 
correction or one way ANOVA were used as 
stated in Figure Legends. Significance is 
indicated as * for p< 0.05, ** for p<0.01 and *** 
for p < 0.001. 
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TABLE 1. Affinities for binding of CC chemokines to CCR1 N-terminal peptides 
Binding constants are reported as pKd values (-log10 of the Kd; in M) ± S.E. The corresponding Kd 
values (in M) are in parentheses. CCL7 in each peptide’s data set was used as a reference for 
statistical analysis. 
Chemokine Competitive Binding pKd 
R1A R1B R1C R1D 
CCL2 5.1 ± 0.07 (9.1) 5.8 ± 0.03 (1.4)*** 6.4 ± 0.04 (0.4)* 6.9 ± 0.05 (0.1)*** 
CCL5 5.8 ± 0.03 (1.7)*** 6.6 ± 0.03 (0.2)*** 6.8 ± 0.02 (0.2)* 7.1 ± 0.03 (0.1)** 
CCL7 5.3 ± 0.05 (4.7) 6.1 ± 0.03 (0.8) 6.6 ± 0.04 (0.2) 7.3 ± 0.02 (0.1) 
CCL8 5.5 ± 0.03 (3.2) 6.2 ± 0.04 (0.6) 7.1 ± 0.01 (0.1)*** 7.4 ± 0.04 (0.04) 
CCL15 4.6 ± 0.06 (23.9)*** 5.1 ± 0.05 (8.8)*** 5.4 ± 0.05 (4.3)*** 5.6 ± 0.04 (2.3)*** 
CCL26 5.4 ± 0.06 (4.0) 6.1 ± 0.05 (0.8) 6.4 ± 0.05 (0.4)* 6.8 ± 0.02 (0.1)*** 
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TABLE 2. Affinities for binding of CC chemokines to CCR1. Binding	was	determined using a 
radioligand (125I- CCL3) displacement assay with membranes prepared from cells grown in the 
absence of chlorate or the presence of 30 mM chlorate to inhibit sulfation for 48 h prior to membrane 
preparation. CCR1 expression was induced by addition of 10 μg/mL tetracycline to the cell media 24 
hours prior to membrane preparation. Inhibition constants are reported as pIC50 values (-log10 of the 
IC50; in M) ± S.E. The corresponding IC50 values (in nM) are in parentheses. CCL7 was used as a 
reference for statistical analysis. 
Chemokine pIC50 (No chlorate treatment) 
pIC50 
(Chlorate-treated cells) 
CCL2 7.2 ± 0.1 (57.5)*** 7.7 ± 0.1 (19.1)*** 
CCL5 9.2 ± 0.2 (0.6) 9.7 ± 0.1 (0.2) 
CCL7 9.6 ± 0.1 (0.4) 9.8 ± 0.1(0.2) 
CCL8 8.7 ± 0.2 (1.8)* 8.7 ± 0.1 (1.9)*** 
CCL15 10.1 ± 0.2 (0.07) 10.0 ± 0.1 (0.1) 
CCL26 no binding 6.3 ± 0.2 (457.1)*** 
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TABLE 3. CCR1 binding and activation parameters for CCL2/CCL7 chimeras 
Binding inhibition constants are reported as pIC50 values (-log10 of the IC50; in M) ± S.E. Potency values for receptor activation are reported as pEC50 values 
(-log10 of the EC50; in M) ± S.E. The corresponding IC50 and EC50 values (in nM) are in parentheses. Maximal effects (Emax) are reported as normalized values: 
the maximal response used for normalization was CCL7 (1 μM) for Arr and GPA assays, forskolin (10 μM) for cAMP assay and FBS (10 %) for pERK assay. 
CCL7 was used as a reference in each assay for statistical analysis. “nd” indicates values that could not be determined from the data. 
  
CCR1 Binding β-Arrestin-2 Assay GPA Assay (αi2) cAMP Assay pERK Assay 
pIC50 pEC50 Emax pEC50 Emax pEC50 Emax pEC50 Emax 
CCL2 7.2 ± 0.2 (57)*** 7.8 ± 0.3 (17) 58.6 ± 8** <6.5 (>300) nd <6.5 (>300) nd 6.9 ± 0.1 (130)*** 24.2 ± 2*** 
CCL2-722 8.0 ± 0.1 (9.3)*** 7.8 ± 0.2 (14) 72.1 ± 6 <6.5 (>300) nd 6.9 ± 0.2 (277)** 38.4 ± 5 7.6 ± 0.2 (24)* 33.7 ± 2* 
CCL2-272 9.0 ± 0.1 (1.0) 7.8 ± 0.1 (16) 70.5 ± 4 <6.5 (>300) nd 7.3 ± 0.1 (54) 42.5 ± 3 7.7 ± 0.2 (22) 31.4 ± 2** 
CCL2-227 7.2 ± 0.1 (63)*** <7.0 (>300) nd <6.5 (>300) nd <6.5 (>300) nd 7.0 ± 0.1 (110)*** 27.1 ± 2*** 
CCL2-777 9.8 ± 0.1 (0.2)*** 8.3 ± 0.1 (5.6) 107.0 ± 6 7.3 ± 0.1 (45.9) 93.6 ± 4 7.6 ± 0.1 (26) 49.5 ± 3 7.8 ± 0.1 (15) 37.8 ± 2 
CCL7 9.0 ± 0.1 (1.0) 8.3 ± 0.1 (5.2) 97.8 ± 5 7.4 ± 0.1 (35.7) 105.5 ± 5 7.9 ± 0.2 (14) 44.2 ± 3 8.2 ± 0.2 (6.0) 43.7 ± 2 
CCL7-277 8.1 ± 0.1 (7.2)*** 8.2 ± 0.2 (6.7) 76.5 ± 6 <6.5 (>300) nd 7.5 ± 0.2 (33) 37.9 ± 3 7.2 ± 0.2 (64)*** 32.3 ± 3** 
CCL7-727 7.8 ± 0.1 (16)*** 8.2 ± 0.2 (6.8) 82.6 ± 6 <6.5 (>300) nd 7.2 ± 0.1 (62)* 39.7 ± 3 7.6 ± 0.1 (24)* 40.5 ± 1 
CCL7-772 8.5 ± 0.2 (3.4)* 8.7 ± 0.2 (2.0) 97.4 ± 7 7.6 ± 0.1 (27.1) 90.4 ± 11 7.9 ± 0.1 (14) 50.3 ± 2 8.2 ± 0.1 (6.8) 50.2 ± 2 
CCL7-222 7.2 ± 0.1 (61)*** nd nd <6.5 (>300) nd <6.5 (>300) nd 6.5 ± 0.1 (350)*** 22.1 ± 3*** 
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FIGURE LEGENDS 
 
 
FIGURE 1. Binding of CC chemokines to CCR1 N-terminal peptides. (A) Sequences of CCR1 
peptides R1A-D; sulfated tyrosine residues (sY) are indicated in bold underlined red font whereas non-
sulfated tyrosine residues are shown in bold black font. (B-G) Competitive binding data and fitted 
curves (solid lines) for displacement of fluorescent peptide Fl-R2D (sequence Fl-
EEVTTFFDsYDsYGAP, in which Fl represents fluorescein and sY represents sulfotyrosine) from (B) 
CCL2, (C) CCL5, (D) CCL7, (E) CCL8, (F) CCL15 and (G) CCL26 using each of the four CCR1 N-
terminal peptides: R1A (blue circles), R1B (red squares), R1C (green triangles) and R1D (purple 
inverted triangles). For all data points, the concentrations of Fl-R2D and the chemokine were 10 and 
100 nM, respectively. Data points represent mean ± SEM of at least three independent experiments 
performed in duplicate. 
 
FIGURE 2. Binding of CC chemokines to CCR1. The radioligand displacement assay was performed 
using 125I-CCL3 as a probe and membrane preparations of Flp-In T-REx HEK293 cells expressing His6-
cMyc-CCR1 grown (A) in the absence and (B) in the presence of 30 mM sodium chlorate. Receptor 
expression was induced 24 hours prior to membrane preparation by addition of 10 μg/mL tet to cell 
media. For the data shown in panel (B), sulfation was inhibited by treatment of the cells with chlorate 
for 48 h prior to membrane preparation. Data points represent means ± SEM of at least three 
independent experiments performed in triplicate. 
 
FIGURE 3. Correlation of chemokines binding affinities of CCR1 and N-terminal peptides. Data 
points represent the pIC50 value for CCR1 (x-axis) and the pKd values for (A) R1A, (B) R1B, (C) R1C 
and (D) R1D (y-axis) for five chemokines; data were not available for CCL26 as it did not bind 
detectably to CCR1 at concentrations tested. Data points represent mean ± SEM of at least three 
independent experiments. For all four graphs the squared correlation coefficient (r2) is ≤0.16. 
 
FIGURE 4. Design and nomenclature of CCL2/CCL7 chimeras. (A) Structure of CCL7 (PDB ID: 
1BO0) showing the three regions swapped in the chimeras. (B) Schematic diagrams of the chimeras 
with regions from CCL2 and CCL7 in blue and red respectively. 
 
FIGURE 5. Binding and activation of CCR1 by CCL2, CCL7 and triple-swap chimeras. (A) 
Competitive displacement was measured using membrane preparations of His6-cMyc-CCR1 Flp-In T-
REx 293 cells and 125I-CCL3 as a probe. (B) β-Arrestin 2 recruitment was measured using parental 
HEK 293 cells transiently transfected with plasmids encoding CCR1-RLuc8 and β-Arr2-YFP. (C) G 
protein activation was measured using His6-cMyc-CCR1 Flp-In T-REx 293 cells and Gαi2. (D) cAMP 
inhibition was measured using His6-cMyc-CCR1 Flp-In T-REx 293 cells transiently transfected with a 
BRET-based cAMP biosensor. (E) ERK1/2 phosphorylation assay was performed using His6-cMyc-
CCR1 Flp-In T-REx 293 cells and the amount of phosphorylated ERK1/2 was measured by 
AlphaScreen detection. Data points represent means ± SEM of at least three independent experiments. 
 
FIGURE 6. Binding and activation of CCR1 by β3 swap chimeras. (A) Competitive displacement, 
(B) β-arrestin 2 recruitment, (C) G protein activation, (D) cAMP inhibition and (E) ERK1/2 
phosphorylation were measured as described for Fig 5. Data points represent means ± SEM of at least 
three independent experiments. 
 
FIGURE 7. Binding and activation of CCR1 by N-loop swap chimeras. (A) Competitive 
displacement, (B) β-arrestin 2 recruitment, (C) G protein activation, (D) cAMP inhibition and (E) 
ERK1/2 phosphorylation were measured as described for Fig 5. Data points represent means ± SEM of 
at least three independent experiments. 
 
FIGURE 8. Binding and activation of CCR1 by N-terminal swap chimeras. (A) Competitive 
displacement, (B) β-arrestin 2 recruitment, (C) G protein activation, (D) cAMP inhibition and (E) 
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ERK1/2 phosphorylation were measured as described for Fig 5. Data points represent means ± SEM of 
at least three independent experiments. 
 
FIGURE 9. Proposed “three-step” model for chemokine receptor binding and activation. (Top) 
Mechanistic model in which the three steps (left to right) represent: (1) fast association of receptor (R) 
and ligand (L) via site 1 to give low affinity, non-specific complex (RLNS); (2) slow formation of site 2 
interactions to give a high affinity, specific complex (RLSpec); and (3) a conformational change to the 
ligand-bound, activated state of the receptor (RLAct). (Bottom) Corresponding, hypothetical free energy 
profile for an agonist (solid black curve) at a concentration (typically 10-100 nM) intermediate between 
the Kd values for high affinity receptor binding and low affinity binding at site 1 only. Also shown are 
the free energy profiles expected for a high affinity antagonist (red curve) a low affinity non-cognate 
ligand (cyan curve) at a similar concentration. The basal activity of the unliganded receptor is 
represented by the dashed black curve. 
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Figure 1. Binding of CC chemokines to CCR1 N-terminal peptides 
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Figure 2. Binding of CC chemokines to CCR1. 
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Figure 3. Correlation of chemokine binding affinities of CCR1 and N-terminal peptides. 
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Figure 4. Design and nomenclature of CCL2/CCL7 chimeras  
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Figure 5. Binding and activation of CCR1 by CCL2, CCL7 and triple-swap chimeras  
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Figure 6. Binding and activation of CCR1 by β3 swap chimeras  
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Figure 7. Binding and activation of CCR1 by N-loop swap chimeras  
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Figure 8. Binding and activation of CCR1 by N-terminal swap chimeras  
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Figure 9. Proposed “three-step” model for chemokine receptor binding and activation.  
 
 
 
